Streetbeat News

Analyst Ratings

COR

B of A Securities has downgraded Cencora from Buy to Neutral and reduced its price target from $275 to $245.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 10:41 am

BDC

Benchmark analyst Reuben Garner maintains a Buy rating on Belden (NYSE:BDC) and raises the price target from $115 to $120.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 10:37 am

ROKU

Needham analyst Laura Martin has reiterated a Buy rating on Roku and maintained a $100 price target.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 10:35 am

ACIU

HC Wainwright & Co. has reiterated its Buy rating on AC Immune (NASDAQ:ACIU) and maintained a price target of $16, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 10:33 am

LSTA

HC Wainwright & Co. has reiterated its Buy rating for Lisata Therapeutics (NASDAQ:LSTA) and maintained a price target of $15, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 10:22 am

LBPH

HC Wainwright & Co. has maintained a Buy rating on Longboard Pharmaceuticals and raised the price target from $60 to $80, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 10:16 am

NEXCF

HC Wainwright & Co. has maintained a Buy rating on Nextech3d AI but lowered the price target from $0.5 to $0.25, indicating a more cautious outlook on the stock's potential.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 10:12 am

RMD

Needham analyst Mike Matson has reiterated a Hold rating on ResMed (NYSE:RMD).

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 10:06 am

SOUN

HC Wainwright & Co. has reiterated its Buy rating for SoundHound AI, maintaining a price target of $7. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 10:04 am

RMD

Wolfe Research has downgraded ResMed (NYSE:RMD) from Peer Perform to Underperform, setting a price target of $180.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 9:52 am